Update on migraine management
- PMID: 35470321
- DOI: 10.1097/GME.0000000000001977
Update on migraine management
Abstract
Migraine is a highly prevalent disorder in women associated with significant disability. Yet it remains underdiagnosed and undertreated. Recent advances in our understanding of the pathophysiology of migraine, including the role of calcitonin gene-related peptide, has led to the development of new targeted migraine therapies. It is important for all healthcare professionals caring for women to be familiar with the diagnostic criteria for migraine and for them to follow a stepwise approach to management of acute and chronic migraine that comprises biobehavioral and pharmacologic management, particularly the more recently approved therapies.
Copyright © 2022 by The North American Menopause Society.
References
-
- Pavlović JM. Evaluation and management of migraine in midlife women. Menopause 2018; 25:927–929.
-
- Lucas S. Migraine and other headache disorders: ACOG clinical updates in women's health care primary and preventive care review summary volume XVIII, number 4. Obstet Gynecol 2019; 134:211.
-
- Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies—successful translation from bench to clinic. Nat Rev Neurol 2018; 14:338–350.
-
- Drugs for migraine. Med Lett Drugs Ther 2020; 62:153–160.
-
- Faubion SS, Batur P, Calhoun AH. Migraine throughout the female reproductive life cycle. Mayo Clin Proc 2018; 93:639–645.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical